ArticleFrontiers in oncology2021

Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer.

Menghao Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.